Scientific Publications
A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154
Leukemia, (30 September 2010) | doi:10.1038/leu.2010.191
Ligation of CD40 on chronic lymphocytic leukemia (CLL) cells induces phenotypic and biochemical changes that facilitate CLL cell–T cell interactions and enhances the
sensitivity of CLL cells to clearance by adaptive and innate immune-effector mechanisms.
Cellular immune therapy for chronic lymphocytic leukemia
Blood, (15 October 2007) Vol. 110, No. 10, pp. 2811-2818.
Although chemotherapy can induce complete responses in patients with chronic lymphocytic leukemia (CLL), it is not considered curative. Treated patients generally develop recurrent disease requiring additional therapy, which can cause worsening immune dysfunction, myelosuppression, and selection for chemotherapy-resistant leukemia-cell subclones.
CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53
Blood, (15 November 2006) Vol. 108, No. 10, pp. 3450-3457
Intravenous infusion of autologous chronic lymphocytic leukemia (CLL) cells transduced with an adenovirus encoding CD40-ligand (CD154) caused rapid reductions in leukemia-cell counts and lymphnode size. We hypothesized that CD40-ligation via CD154 sensitized CLL cells to death-receptor-mediated apoptosis.